Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive ...

CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that ...

The MarketWatch News Department was not involved in the creation of this content. -- Financing led by US life sciences investor, BroadOak Capital Partners -- Investment to support expansion of US ...

Take your neuroimmunology research to the next level! Our Human iPSC-derived Microglia are suitable for a variety of applications including in vitro disease models, phenotypic screening and immunology ...

CAMBRIDGE, England & EDINBURGH, Scotland & GRASSE, France--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today ...

Axol Bioscience and Censo Biotechnologies have merged to set up a one-stop-shop for induced pluripotent stem cells (iPSCs). IPSCs are derived from skin or blood cells that have been reprogrammed back ...

The relationship brings together Horizon’s precision genome editing capability and Axol’s expertise in iPSC reprogramming and differentiation to provide isogenic cell lines for neuronal and ...

Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Axol Bioscience – a stem ...

Financing led by US life sciences investor, BroadOak Capital Partners Investment to support expansion of US operations, product development, and cell manufacturing scale-up Axol Bioscience Ltd. (Axol) ...

Financing led by US life sciences investor, BroadOak Capital Partners Investment to support expansion of US operations, product development, and cell manufacturing scale-up CAMBRIDGE, England & ...